spot_img
3.6 C
London
HomeInvestors HealthMerck, Daiichi post trial data for lung cancer drug (NYSE:MRK)

Merck, Daiichi post trial data for lung cancer drug (NYSE:MRK)


Cancer cells vis

koto_feja

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd), which belongs to a novel cancer drug class called antibody-drug conjugates (ADC).

Citing an



Source link

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here